Reshape Biotech vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Copenhagen YC W21 lab automation robots for biotech at $28.2M total ($20M Astanor Series A Apr 2024) and $8.3M revenue 2024; 500K+ hours saved annually serving alternative protein and sustainable ag competing with Opentrons for microbiology automation.
About
Reshape Biotech is a Copenhagen, Denmark-based laboratory automation robotics company — backed by Y Combinator (W21) with $28.2 million in total funding including a $20 million Series A led by Astanor Ventures in April 2024 with participation from YC — providing biotechnology companies, life sciences research organizations, and food technology companies with specialized single-function robots that automate repetitive microbiological laboratory workflows, generating $8.3 million in annual revenue in 2024 with a 55-person team. Reshape's robots have saved customers over 500,000 hours of manual lab work annually, serving the sustainable food technology and alternative protein sector (fermentation-based food production, precision fermentation, cultivated meat) alongside traditional biotech research laboratories that use microbiology workflows at scale.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.